Brain-Computer Interface Startup Gestala Raises $21M in Record China BCI Round
Chinese ultrasound brain-computer interface startup Gestala has secured $21.6 million in funding just two months after its founding — setting a new record for early-stage BCI investment in China. Founded by serial entrepreneur Phoenix Peng, Gestala is developing non-invasive brain-computer interfaces that could change how humans interact with technology, without the need for surgery.
 |
| Credit: Yuichiro Chino / Getty Images |
A Record-Breaking Round That Nobody Expected This Fast
When a startup raises a nine-figure valuation within its first sixty days of existence, the industry takes notice. Gestala, valued between $100 million and $200 million, closed a CN¥150 million ($21.6 million) funding round co-led by Guosheng Capital and Dalton Venture. The round also attracted participation from Tsing Song Capital, Gobi Ventures, Fourier Intelligence, Liepin, and Seas Capital. What's even more striking is that investor demand far exceeded the raise itself — total commitments surpassed $58 million, meaning the round was oversubscribed by nearly three times. For a company that barely had time to print business cards, this is a remarkable signal of where smart money is heading.
Who Is Phoenix Peng — and Why Is He Building Two BCI Companies?
Phoenix Peng is not new to the brain-computer interface world. He is already the founder of NeuroXess, a company developing implantable BCI systems that require surgical insertion. Gestala, his second BCI venture, takes a deliberately different path — one that doesn't require cutting into the skull at all. Peng is essentially building on two sides of the same bet: that brain-computer interfaces will become mainstream technology within this decade, and that different use cases will require different approaches. The implantable route is designed for patients with severe neurological conditions. The non-invasive route, which Gestala is pursuing, is aimed at a far broader population — potentially everyone.
Why Ultrasound? The Science Behind the Bet
The core technology inside Gestala's approach is focused ultrasound — a method that uses sound waves to interact with neural activity through the skull, without any incisions. Ultrasound-based BCIs are generating serious scientific interest because they offer something electrode-based implants simply cannot: access to deep brain structures across a wider region, not just localized surface areas. Peng believes this gives ultrasound the potential to become the next generation of brain-computer interface technology, offering whole-brain interaction rather than a narrow neural window. The ability to monitor and potentially stimulate broader brain networks opens the door to applications far beyond medical use — including cognitive enhancement, immersive computing, and entirely new forms of human-machine communication. It is an ambitious vision, but one increasingly backed by peer-reviewed neuroscience research.
Solving BCI's Biggest Problem: The Surgery Barrier
One of the most significant obstacles holding back brain-computer interface adoption is not the technology — it is fear of going under the knife. The idea of having electrodes drilled into your skull remains a non-starter for most people, regardless of the potential benefits. This is precisely the problem that non-invasive ultrasound BCI aims to solve. By working through the skull without any physical insertion, Gestala's technology sidesteps the surgical risk entirely. For patients with conditions like paralysis or severe depression, this could mean access to life-changing treatments that were previously out of reach. For healthy users, it opens up an entirely new category of wearable neurotechnology that doesn't require a hospital visit or a recovery period. If the technology delivers on its promise, the addressable market expands from thousands of clinical patients to potentially billions of everyday users.
China's BCI Race Is Just Getting Started
Gestala holds a notable distinction: it is the first ultrasound BCI company in China, though several similar companies have launched in the United States in recent years. This positions Gestala at the frontier of a domestic industry that is accelerating rapidly. China has been aggressively investing in neurotechnology as part of its broader push into deep-tech sectors, and early-stage BCI funding in the country has been growing year over year. Gestala's raise — described as the largest early-stage BCI funding in Chinese history — signals that local investors are ready to write serious checks for the space. The timing is not accidental. As Western BCI companies attract global attention, Chinese investors appear eager to back a homegrown competitor before valuations climb further.
What the $21M Will Actually Build
Peng has been clear about how the capital will be deployed. The funding will go toward three priorities: research and development, team expansion, and manufacturing infrastructure. The company currently employs around 15 people and plans to grow that headcount to approximately 35 by the end of 2026. Gestala is also building a dedicated manufacturing facility in China, signaling that the team is not just doing academic research — they are moving toward production. The most closely watched milestone will be the completion of Gestala's first-generation prototype, which Peng expects to achieve by year-end. For a three-month-old startup, that is an aggressive timeline, but with a fully funded war chest and a growing team, the company appears to be building with genuine urgency.
The Global BCI Landscape Is Heating Up Fast
The race to commercialize brain-computer interfaces is no longer a fringe conversation — it is a full-scale industry sprint. Neuralink has successfully implanted its device in multiple human subjects, with early results showing paralyzed patients able to control computers using thought alone. Non-invasive BCI ventures are actively pursuing the same lane in the United States, attracting significant attention from the AI investment community. Now Gestala is entering the picture as China's answer to both approaches. The convergence of artificial intelligence, advanced materials science, and miniaturized ultrasound hardware is creating a window of opportunity that did not exist even five years ago. Investors who missed the early days of mobile computing or large language models are watching this space with intense focus. The BCI wave is building — and Gestala just paddled hard to catch it early.
What Comes Next for Gestala
The months ahead will be defining ones for Gestala and for non-invasive BCI technology broadly. Delivering a working first-generation prototype is the immediate test — demonstrating that focused ultrasound can produce reliable, repeatable neural interaction outside a controlled laboratory environment. Beyond the prototype, the company will need to navigate regulatory approvals, clinical validation, and eventually consumer or enterprise product development. None of those steps are simple, and the history of neurotechnology is littered with promising companies that never made it past the research phase. But the combination of a record funding round, a heavily oversubscribed investor list, and a founder who has already built in this space suggests Gestala is approaching the challenge with both ambition and credibility. The brain-computer interface era is arriving. The only question now is who builds it first.
